RxDoctor Payments Data

Milla Stelman, MD

Family Medicine · Trumbull, CTNPI 1538113139

Payments from drug & device makers

$1,600in general payments, 2019–2025

Across 14 payments — averaging $114.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$500
  • Abbott$382
  • Medtronic$135
  • Lilly USA, LLC$133
  • Astellas Pharma US Inc$125
  • Boehringer Ingelheim$125
  • plus $200 from 3 others

What the payments were for

  • Speaking & faculty fees$31019%
  • Food & beverage$1,28280%
  • Education$81%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)3$500
Abbott3$382
Medtronic1$135
Lilly USA, LLC2$133
Astellas Pharma US Inc1$125
Boehringer Ingelheim1$125
Johnson & Johnson1$122
Sanofi1$60
GSK1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,600 in reported general payments places this provider in the 75th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$85,852
Medicare patients
232
Services billed
1,234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate19$172,553
OzempicSemaglutide58$75,742
JardianceEmpagliflozin87$59,929
EliquisApixaban117$42,969
JanuviaSitagliptin Phosphate87$41,344
FarxigaDapagliflozin Propanediol57$39,918
MounjaroTirzepatide29$35,100
TradjentaLinagliptin72$31,651
RybelsusSemaglutide21$31,219
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$29,860
LinzessLinaclotide40$27,437
TrulicityDulaglutide25$26,012
MyrbetriqMirabegron52$20,208
Janumet XrSitagliptin Phos/Metformin Hcl23$16,666
Tresiba Flextouch U-200Insulin Degludec18$15,400

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$125$91,580159 claims
Lilly USA, LLCMounjaro, Trulicity$133$61,11354 claims
GSKTrelegy Ellipta, Anoro Ellipta$18$35,54854 claims
AbbVieLinzess, Restasis$500$32,41051 claims
Astellas Pharma US IncMyrbetriq$125$20,20852 claims
Johnson & JohnsonXarelto, Procrit$122$14,90036 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Trumbull

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →